Geminiviral vector for expression of rituximab
US10125373B2 · kind B2 · utility
17Cited by
108References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 22, 2014 |
| Grant date | Nov 13, 2018 |
| Priority date | — |
| Expiry date | Nov 2, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/12043
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures to optimize the expression is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of the multi-replicon single vector system for producing Rituximab in plant cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.